How much of Atea Pharmaceuticals’ revenue comes from haram?

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for life-threatening viral infections.

The company’s lead product for treating patients with COVID-19, AT-527, is an orally administered direct-acting antiviral. 

Atea earns its revenue primarily through collaboration agreements with Roche.

Practical Islamic Finance concludes:

None of Atea Pharmaceuticals’ revenue comes from anything inherently haram.

Does Atea Pharmaceuticals rely on interest to operate?

Year-to-Date
for period ended
6/30/2021
Fiscal year
ended
12/31/2020
Fiscal year
ended
12/31/2019
Interest Income$109$83$574
Total Revenue$126,376$48,633
Interest Expense
Total Expenses$87,033$59,663$14,608
Interest Income / Revenue0.09%0.17%
Interest Expense / Total Expense
*Numbers in thousands, U.S. dollars

Practical Islamic Finance concludes: 

Riba is used but not relied upon in Atea Pharmaceuticals’ operations.

What is Atea Pharmaceuticals’ Environmental, Social, and Governance (ESG) impact?

Environment

No notable environmental highlights.

Social

Atea Pharmaceuticals has a Glassdoor rating of 3.7 out of 5.0 from over 60 current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.

Governance

No notable governance highlights.

Practical Islamic Finance concludes:

Atea Pharmaceuticals has a net positive ESG impact.

Comfort Rating

From Atea Pharmaceuticals’ business, financial, and ESG reviews, Practical Islamic Finance rates Atea Pharmaceuticals stock as:

Comfortable to invest in from a Halal perspective.

Sources

Atea Reviews 

Atea Pharmaceuticals Q2 2021 10-Q

Atea Pharmaceuticals 2020 10-K